Biotech Companies Go Public at a Blistering Pace

The transcript discusses the trends in IPOs, highlighting a significant increase in public offerings compared to previous years. It explores the biotech sector's funding landscape, emphasizing the availability of private capital and the example of Moderna Therapeutics. The discussion also covers investment themes in therapies, particularly in cancer and rare diseases, noting recent breakthroughs and the potential for high returns.

What is the trend in the number of IPOs in recent years compared to 2014?

• The number of IPOs has decreased significantly.

• The number of IPOs has remained the same.

• The number of IPOs has surpassed the 2014 record.

• The number of IPOs has increased but is still below the 2014 record.

Why has Moderna Therapeutics remained a private company for so long?

• Because its investors have been very generous.

• Due to lack of interest from public investors.

• Because it has not developed any significant therapies.

• Due to regulatory issues.

What is Moderna Therapeutics working on that is considered groundbreaking?

• Traditional cancer therapies.

• Checkpoint inhibitors.

• Therapies on messenger RNA.

• Gene editing for rare diseases.

Which two main categories of therapies are attracting significant investment in biotech?

• Cancer and rare diseases.

• Respiratory diseases and autoimmune disorders.

• Cardiovascular diseases and diabetes.

• Neurological disorders and infectious diseases.

What recent advancements have been made in cancer therapies?

• Development of new antibiotics.

• Introduction of gene editing in clinics.

• Advancements in traditional chemotherapy.

• Discovery of new vaccines.